321
118. Ngo HT, Hetland RB, Sabaredzovic A, Haug LS, Steffensen I-L. In utero exposure to perfluorooctanoate (PFOA) or perfluorooctane sulfonate (PFOS) did not increase body weight
or intestinal tumorigenesis in multiple intestinal neoplasia (Min/+) mice. Environ Res.
2014;132:251–63.
119. Halldorsson TI, Rytter D, Haug LS, Bech BH, Danielsen I, Becher G, et al. Prenatal exposure
to perfluorooctanoate and risk of overweight at 20 years of age: a prospective cohort study.
Environ Health Perspect. 2012;120(5):668–73.
120. Mora AM, Oken E, Rifas-Shiman SL, Webster TF, Gillman MW, Calafat AM, et al. Prenatal
exposure to perfluoroalkyl substances and adiposity in early and mid-childhood. Environ
Health Perspect. 2016;125(3):467–73.
121. Andersen CS, Fei C, Gamborg M, Nohr EA, Sørensen TI, Olsen J. Prenatal exposures to perfluorinated chemicals and anthropometry at 7 years of age. Am J Epidemiol.
2013;178(6):921–7.
122. Grün F, Blumberg B. Environmental obesogens: organotins and endocrine disruption via
nuclear receptor signaling. Endocrinology. 2006;147(6):s50–s5.
123. Hurst CH, Waxman DJ. Activation of PPARα and PPARγ by environmental phthalate monoesters. Toxicol Sci. 2003;74(2):297–308.
124. Long M, Ghisari M, Bonefeld-Jørgensen EC. Effects of perfluoroalkyl acids on the function of the thyroid hormone and the aryl hydrocarbon receptor. Environ Sci Pollut Res.
2013;20(11):8045–56.
125. Jensen AA, Leffers H. Emerging endocrine disrupters: perfluoroalkylated substances. Int J
Androl. 2008;31(2):161–9.
126. Chen F, Yin S, Kelly BC, Liu W. Isomer-specific transplacental transfer of perfluoroalkyl
acids: results from a survey of paired maternal, cord sera, and placentas. Environ Sci Technol.
2017;51(10):5756–63.
127. Li M, Zeng X-W, Qian ZM, Vaughn MG, Sauvé S, Paul G, et al. Isomers of perfluorooctanesulfonate (PFOS) in cord serum and birth outcomes in China: Guangzhou Birth Cohort Study.
Environ Int. 2017;102:1–8.
128. Jornayvaz FR, Vollenweider P, Bochud M, Mooser V, Waeber G, Marques-Vidal P. Low birth
weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus study.
Cardiovasc Diabetol. 2016;15(1):73.
129. Karnes C, Winquist A, Steenland K. Incidence of type II diabetes in a cohort with substantial
exposure to perfluorooctanoic acid. Environ Res. 2014;128:78–83.
130. Conway B, Innes KE, Long D. Perfluoroalkyl substances and beta cell deficient diabetes. J
Diabetes Complicat. 2016;30(6):993–8.
131. Christensen KY, Raymond M, Thompson BA, Anderson HA. Perfluoroalkyl substances in
older male anglers in Wisconsin. Environ Int. 2016;91:312–8.
132. Su T-C, Kuo C-C, Hwang J-J, Lien G-W, Chen M-F, Chen P-C. Serum perfluorinated chemicals, glucose homeostasis and the risk of diabetes in working-aged Taiwanese adults. Environ
Int. 2016;88:15–22.
133. Rosen MB, Lee JS, Ren H, Vallanat B, Liu J, Waalkes MP, et al. Toxicogenomic dissection of
the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of
nuclear receptors PPARα and CAR. Toxicol Sci. 2008;103(1):46–56.
134. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53(1):409–35.
135. Scharmach E, Buhrke T, Lichtenstein D, Lampen A. Perfluorooctanoic acid affects the activity of the hepatocyte nuclear factor 4 alpha (HNF4α). Toxicol Lett. 2012;212(2):106–12.
136. Hayhurst GP, Lee Y-H, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4α
(nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid
homeostasis. Mol Cell Biol. 2001;21(4):1393–403.
137. Ohguchi H, Tanaka T, Uchida A, Magoori K, Kudo H, Kim I, et al. Hepatocyte nuclear factor 4α contributes to thyroid hormone homeostasis by cooperatively regulating the type 1
iodothyronine deiodinase gene with GATA4 and Krüppel-like transcription factor 9. Mol Cell
Biol. 2008;28(12):3917–31.
18 Role of Perfluoroalkyl Substances as EDCs in Metabolic Disorders
118. Ngo HT, Hetland RB, Sabaredzovic A, Haug LS, Steffensen I-L. In utero exposure to perfluorooctanoate (PFOA) or perfluorooctane sulfonate (PFOS) did not increase body weight
or intestinal tumorigenesis in multiple intestinal neoplasia (Min/+) mice. Environ Res.
2014;132:251–63.
119. Halldorsson TI, Rytter D, Haug LS, Bech BH, Danielsen I, Becher G, et al. Prenatal exposure
to perfluorooctanoate and risk of overweight at 20 years of age: a prospective cohort study.
Environ Health Perspect. 2012;120(5):668–73.
120. Mora AM, Oken E, Rifas-Shiman SL, Webster TF, Gillman MW, Calafat AM, et al. Prenatal
exposure to perfluoroalkyl substances and adiposity in early and mid-childhood. Environ
Health Perspect. 2016;125(3):467–73.
121. Andersen CS, Fei C, Gamborg M, Nohr EA, Sørensen TI, Olsen J. Prenatal exposures to perfluorinated chemicals and anthropometry at 7 years of age. Am J Epidemiol.
2013;178(6):921–7.
122. Grün F, Blumberg B. Environmental obesogens: organotins and endocrine disruption via
nuclear receptor signaling. Endocrinology. 2006;147(6):s50–s5.
123. Hurst CH, Waxman DJ. Activation of PPARα and PPARγ by environmental phthalate monoesters. Toxicol Sci. 2003;74(2):297–308.
124. Long M, Ghisari M, Bonefeld-Jørgensen EC. Effects of perfluoroalkyl acids on the function of the thyroid hormone and the aryl hydrocarbon receptor. Environ Sci Pollut Res.
2013;20(11):8045–56.
125. Jensen AA, Leffers H. Emerging endocrine disrupters: perfluoroalkylated substances. Int J
Androl. 2008;31(2):161–9.
126. Chen F, Yin S, Kelly BC, Liu W. Isomer-specific transplacental transfer of perfluoroalkyl
acids: results from a survey of paired maternal, cord sera, and placentas. Environ Sci Technol.
2017;51(10):5756–63.
127. Li M, Zeng X-W, Qian ZM, Vaughn MG, Sauvé S, Paul G, et al. Isomers of perfluorooctanesulfonate (PFOS) in cord serum and birth outcomes in China: Guangzhou Birth Cohort Study.
Environ Int. 2017;102:1–8.
128. Jornayvaz FR, Vollenweider P, Bochud M, Mooser V, Waeber G, Marques-Vidal P. Low birth
weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus study.
Cardiovasc Diabetol. 2016;15(1):73.
129. Karnes C, Winquist A, Steenland K. Incidence of type II diabetes in a cohort with substantial
exposure to perfluorooctanoic acid. Environ Res. 2014;128:78–83.
130. Conway B, Innes KE, Long D. Perfluoroalkyl substances and beta cell deficient diabetes. J
Diabetes Complicat. 2016;30(6):993–8.
131. Christensen KY, Raymond M, Thompson BA, Anderson HA. Perfluoroalkyl substances in
older male anglers in Wisconsin. Environ Int. 2016;91:312–8.
132. Su T-C, Kuo C-C, Hwang J-J, Lien G-W, Chen M-F, Chen P-C. Serum perfluorinated chemicals, glucose homeostasis and the risk of diabetes in working-aged Taiwanese adults. Environ
Int. 2016;88:15–22.
133. Rosen MB, Lee JS, Ren H, Vallanat B, Liu J, Waalkes MP, et al. Toxicogenomic dissection of
the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of
nuclear receptors PPARα and CAR. Toxicol Sci. 2008;103(1):46–56.
134. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53(1):409–35.
135. Scharmach E, Buhrke T, Lichtenstein D, Lampen A. Perfluorooctanoic acid affects the activity of the hepatocyte nuclear factor 4 alpha (HNF4α). Toxicol Lett. 2012;212(2):106–12.
136. Hayhurst GP, Lee Y-H, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4α
(nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid
homeostasis. Mol Cell Biol. 2001;21(4):1393–403.
137. Ohguchi H, Tanaka T, Uchida A, Magoori K, Kudo H, Kim I, et al. Hepatocyte nuclear factor 4α contributes to thyroid hormone homeostasis by cooperatively regulating the type 1
iodothyronine deiodinase gene with GATA4 and Krüppel-like transcription factor 9. Mol Cell
Biol. 2008;28(12):3917–31.
18 Role of Perfluoroalkyl Substances as EDCs in Metabolic Disorders